Advancements in CLL Treatment

This chapter explores the evolving landscape of Chronic Lymphocytic Leukemia (CLL) therapies, particularly focusing on the impact of BTK inhibitors and the comparison of obinutuzumab versus rituximab. It highlights the significance of recent trials, treatment duration, and the role of venetoclax, while addressing patient-specific considerations in treatment choices.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.